Latest Camurus News & Updates

See the latest news and media coverage for Camurus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Camurus

Biopharmaceutical company developing long-acting treatments for severe chronic diseases

camurus.com

Headquarters: Lund, Sweden
Founded year: 1991
Company type: Public company
Number of employees: 300–500
Industry: Pharmaceuticals

Last updated October 11

Latest news about Camurus

In short: Camurus won Canadian approval for Oczyesa XR, advanced CAM2029 in the US, and grew Q2 revenue.

Company announcements

October 1 Camurus

Camurus presents its October 2026 business update

The company reports double-digit revenue growth, strong profitability, and significant pipeline progress including Oczyesa launches and positive clinical results for CAM2029.

July 17 Camurus

Camurus' application for CAM2029 accepted by FDA

Target date for approval decision is December 18, 2026. The application concerned cGMP observations, not clinical data.

July 15 Camurus

Camurus reports strong Q2 2026 results with revenue growth

Revenue reached SEK 702 million, driven by Buvidal sales growth. The company maintains a robust cash position of SEK 4.1 billion.

June 10 Camurus

Camurus updates on regulatory process for CAM2029 in the USA

FDA issued a request for additional information regarding the application for marketing approval for CAM2029 (Oclaiz) for acromegaly.

Media coverage

October 11 Marketscreener

Camurus receives approval in Canada for Oczyesa XR

The research-based pharmaceutical company Camurus has received marketing authorization in Canada for Oczyesa XR, a monthly depot for maintenance therapy in adults with acromegaly who...

October 5 Dagens industri

Nordea sees 56 percent upside on Camurus stock

Low expectations and gloomy sentiment create potential for a rapid price increase if the company beats forecasts, according to analysis from Nordea.

September 18 MarketScreener

Camurus AB Stock Börse Stuttgart

Jul. 17 US FDA Accepts Camurus' Resubmitted Application for Acromegaly Treatment CAM2029 MT Jul. 17 Camurus NDA Resubmission for CAM2029 in Acromegaly Accepted for Review...

July 17 Endocrinology Advisor

FDA Accepts Camurus’ Resubmitted NDA for CAM2029 in Acromegaly

The FDA has accepted Camurus' resubmitted NDA for CAM2029 (octreotide) extended-release injection for acromegaly, setting a PDUFA date of December 18, 2026.

Never miss news about Camurus

Track Camurus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Camurus competitors & trending companies

Browse news for competitors to Camurus and other trending companies.